LCT Share Price

Open 0.10 Change Price %
High 0.10 1 Day 0.01 11.11
Low 0.09 1 Week 0.01 11.11
Close 0.10 1 Month 0.02 25.00
Volume 639473 1 Year 0.05 100.00
52 Week High 0.11
52 Week Low 0.04
LCT Important Levels
Resistance 2 0.11
Resistance 1 0.11
Pivot 0.10
Support 1 0.09
Support 2 0.09
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
GPP 0.03 0.00%
PDN 0.06 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
GMR 0.01 0.00%
GMR 0.01 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
RMG 0.02 100.00%
RMG 0.02 100.00%
GME 0.03 50.00%
GME 0.03 50.00%
GME 0.03 50.00%
GME 0.03 50.00%
RHT 0.03 50.00%
RHT 0.03 50.00%
BMN 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GTG 0.01 -50.00%
RFT 0.02 -33.33%
AVX 0.02 -33.33%
AVX 0.02 -33.33%
AVX 0.02 -33.33%
More..

Living Cell Technologies Ltd (ASX: LCT)

LCT Technical Analysis 5
As on 2nd Dec 2016 LCT Share Price closed @ 0.10 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.07 & Strong Buy for SHORT-TERM with Stoploss of 0.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
LCT Target for December
1st Target up-side 0.1
2nd Target up-side 0.11
3rd Target up-side 0.12
1st Target down-side 0.08
2nd Target down-side 0.07
3rd Target down-side 0.06
LCT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.lctglobal.com
LCT Address
LCT
Hunters Corner
PO Box 23566
Auckland, 2155
New Zealand
Phone: 64 9 276 2690
Fax: 64 9 276 2691
LCT Latest News
Interactive Technical Analysis Chart Living Cell Technologies Ltd ( LCT ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Living Cell Technologies Ltd
LCT Business Profile
Living Cell Technologies Limited, a cell implant company, develops living cell products for the treatment of diabetes and neurological diseases primarily in New Zealand. The company’s technology, IMMUPEL, coats cells with protective capsules that prevent them from attack by the patient’s immune system. Its product pipeline includes DIABECELL, a porcine insulin-producing cell product for the treatment of type 1 diabetes; and NTCELL, a choroid plexus cell product to treat Parkinson's disease and other disorders, such as stroke, Huntington's disease, and hearing loss, as well as wound hearing. Living Cell Technologies Limited was founded in 1987 and is based in Auckland, New Zealand.